🚨New in @EUPlatinum! 📌 PSMA PET for Prostate Cancer Diagnosis & Staging by Elio Mazzone et al 🧠 This comprehensive meta-analysis confirms the high diagnostic value of PSMA PET—especially when combined with MRI—but reminds us it’s not enough to skip biopsy or lymph node

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant #ProstateCancer #VIOLET: A single-centre, single-arm, phase I/II study. Presentation by James Buteau Peter Mac Cancer Centre #SNMMI25 written coverage by Rashid K. Sayyid

🚨Detecting cribriform & IDC on MRI-guided prostate biopsy among pts w/ GG2-3 #prostatecancer🚨 👏First-author Raeven Grant (she/her) David Geffen School of Medicine at UCLA just out in ACS Journal Cancer 👉641 pts & 1186 GG2-3 tumors on MRI-guided biopsy 🔬Sensitivity for detecting cribriform, IDC, or either is

🎗️ Oncology for the Non-Oncologist 🎗️ Thread: Oncology Emergencies You Can’t Miss Interns listen up - 🧵

UPDATED! The definitive systematic reviews of PSMA PET/CT in European Urology. Mazzone et al taking over from Perera et al. We discuss with Elio Mazzone Alberto Briganti marlon perera youtu.be/7nIaOPEzxKY

Cedar You It gets easier. Also, if you jog super slow the first mile, then everything after that is a lot easier. Just give your body some time to wake up and get into the rhythm of it. A lot of people push too hard right away, and then get burned out before they ever really got going.

While phase 3 oncology trials frequently report success based on alternative endpoints, actual enhancements in overall survival and quality of life are uncommon. ja.ma/4m3Eesv Alexander Sherry Bishal Gyawali, MD, PhD, FASCO Pavlos Msaouel Ethan Ludmir MD

Ambushed by these two rad oncs Shankar Siva Dr. Andrew Loblaw Sounded like they were taking me to a surgical technology launch but it was a CyberKNIFE launch! Robotic radio-surgery they say #notarealknife but impressive kit! marlon perera David Chen. GU Cast coming soon! GU Cast | Urology podcast!

This has always been our bottom line. academic.oup.com/jnci/advance-a…

Radiation Units:

Following a recent EOI process, BJU International have announced the new Editor for the BJUI USANZ Supplement. The role will be shared between marlon perera and A/Prof Matthew Roberts. We thank the outgoing editor Nathan Lawrentschuk for his ten years of service to USANZ and Urology.

Terbium-161 vs lutetium-177: Comparing next-gen radioligands for #ProstateCancer. Michael Hofman Peter Mac Cancer Centre joins Oliver Sartor, MD East Jefferson General Hospital to discuss the #VIOLET study evaluating Terbium-161 PSMA therapy in #mCRPC. #WatchNow > bit.ly/46AXlG8

Augerlicious: Terbium-161 Double Punch to Cancer Cells FREE WEBINAR Coming up Sep 17/18 !!! Don't miss it, register now: link.prostic.org/webinar Is Terbium-161 superior to Lutetium-177? You'll hear about the latest clinical trials, experience and translational research from

#PRIMARY2 was a rather crazy (ambitious) idea a few years ago: run of randomised trial of 660 patients to determine if PSMA PET can improve DIAGNOSIS of prostate cancer in selected men with uncertain findings on MRI, potentially reducing the need for painful biopsies.

The hardest lessons after training aren’t always in the OR or clinic. 🙏 I wrote this essay for anyone navigating their first year as an attending. “Unseen Scars” in JAMA 🔗jamanetwork.com/journals/jama/…

Shaping the future of Lu-177 PSMA-617 radiopharmaceutical therapy in prostate cancer: is earlier better, or is patient selection key? authors.elsevier.com/a/1lsTb_L0FFUT… Arun Azad Annals of Oncology #PSMAfore

The AlphaBet trial Peter Mac Cancer Centre The Lancet Oncology release today ESMO - Eur. Oncology #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future

Early stable or rising PSA does not preclude subsequent biochemical or pain response with additional cycles of ¹⁷⁷Lu-PSMA-617 treatment. ow.ly/MXYY50Xc7eB #NuclearMedicine #ProstateCancer #RPTherapy David Chen Michael Hofman Arun Azad

1/ 🚨 Pleased to share that our latest manuscript is out now in European Urology! Baseline and on-treatment #ctDNA biomarkers in men with advanced #ProstateCancer treated with #LuPSMA. bit.ly/4nzJRyV Thanks to Louise Kostos Heidi Fettke Peter Mac Cancer Centre